3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
3
Gastrointestinal
3
CNS
3
Sarcoma
2
Lymphoid
2
Genitourinary
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Endocrine
1
Dermatologic
1
Conditions
Ovarian Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
trametinib
2
dabrafenib
2
Temozolomide
2
Paclitaxel
2
Nivolumab
2
Carboplatin
2
ulixertinib
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
entinostat
1
diazepinomicin
1
defactinib
1
copanlisib
1
cobimetinib
1
cediranib
1
carboxyamido-triazole
1
capivasertib
1
cabiralizumab
1
binimetinib
1
adavosertib
1
X-Rays
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
Vemurafenib
×
Gynecologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled